Leland Gershell

Raghuram Selvaraju

Aydin Huseynov

Paul Choi

Tara Bancroft

Kelsey Goodwin

Michael Schmidt

George Farmer

Kyuwon (Paul) Choi

Matthew Kaplan

- UroGen Pharma's new product, Zasturi, targets the low-grade intermediate non-muscle invasive bladder cancer (NMIBC) market, which represents a **$5+ billion** total available market, significantly larger than their first product, Jelmyto.  **[1668243_tx_378149_1]**  Zasturi has demonstrated strong efficacy, with **80% of patients achieving a complete response** and **72% remaining recurrence-free at 24 months**.  **[1668243_tx_378149_3]** 
- A key commercialization barrier for Zasturi in community settings is the current miscellaneous J-code, which causes reimbursement concerns.  **[1668243_tx_378149_5]**  A permanent J-code is expected on **January 1**, which is anticipated to **accelerate adoption**.  **[1668243_tx_378149_5]** **[1668243_tx_378149_6]** 
- The company projects that its current cash reserves will lead to profitability.  **[1668243_tx_378149_7]**  They anticipate Jelmyto revenues between **$94 million and $98 million** for the current year and estimate Zasturi's peak potential to be **over $1 billion**, with a path to profitability in about **five years** at peak sales.  **[1668243_tx_378149_7]** 
- UroGen is developing UGN-103 as a life cycle management strategy for Zasturi, which offers patent protection until **December 2041**, significantly extending beyond Zasturi's **February 2031** patent expiry.  **[1668243_tx_378149_8]**  UGN-103 is expected to be filed in **2026** and approved in **2027**, after which Zasturi would be taken off the market.  **[1668243_tx_378149_8]**

UroGen Pharma Discusses Zasturi Commercialization, Pipeline, and Path to Profitability

UroGen Pharma (URGN)